利拉鲁肽辅助治疗调控初发2型糖尿病伴肥胖患者代谢紊乱的效果研究.

Objective To investigate the efficacy of liraglutide as an adjunct therapy in regulating metabolic disorders in obese patients with newly diagnosed type 2 diabetes. Methods This prospective study selected 116 patients diagnosed with newly onset type 2 diabetes and obesity due to metabolic disorders from April 2022 to April 2023. Patients were divided into four groups based on their medication regimen: Metformin-1 group, Metformin-2 group, Empagliflozin-1 group, and Empagliflozin-2 group. The Metformin-1 and Empagliflozin-1 groups received monotherapy with Metformin and Empagliflozin, respectively, while the Metformin-2 and Empagliflozin-2 groups received liraglutide in addition to their respective monotherapies over a 12-week treatment period. Changes in obesity indices [(body mass index(BMI), waist circumference], glucose metabolism indices [fasting plasma glucose(FPG), 2-hour postprandial glucose(2 hPG), glycated hemoglobin(HbA1C)], lipid metabolism indices [high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C), total cholesterol(TC), triglycerides(TG)], insulin resistance index(HOMA-IR), pancreatic β-cell function index(HOMA-β), total adiponectin(tAPN), irisin, and serum secreted frizzled-related protein 5(SFRP5) were observed. Adverse reactions were also recorded during treatment.Results At baseline(T0), there were no significant differences among the four groups regarding obesity indices, glucose metabolism indices, lipid metabolism indices, HOMA-IR, HOMA-β, tAPN, irisin, and SFRP5(P＞0.05). Similarly, comparisons between Metformin-1 and Empagliflozin-1 groups at T1 showed no significant differences(P＞0.05). However, the improvements in T1 for obesity, glucose, and lipid metabolism indices, HOMA-IR, HOMA-β, tAPN, irisin, and SFRP5 were significantly more pronounced in the Metformin-2 and Empagliflozin-2 groups compared to their respective monotherapy groups(P＜0.05). The overall incidence of adverse reactions, including headache, dizziness, gastrointestinal reactions, urinary infections, and hypoglycemia, did not differ significantly among the groups(P＞0.05).Conclusion For obese patients with newly diagnosed type 2 diabetes, early health education and treatment with Metformin or Empagliflozin are effective. The addition of liraglutide as an adjunct therapy significantly enhances metabolic improvement and weight control without increasing adverse reactions, suggesting that liraglutide is a valuable adjunct treatment for metabolic disorders in these patients and can be promoted for clinical use. [ABSTRACT FROM AUTHOR]